# Jeffrey Moore

> Jeffrey Moore is a seed investor at MP Healthcare Venture Management backing Biotechnology. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [MP Healthcare Venture Management](https://shizune.co/investors/profile/mp-healthcare-venture-management-inc)
- Location: Boston, United States
- Total investments: 6
- Last investment: Jun 2026
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/jeffreymoore

Jeffrey Moore is a seed investor at MP Healthcare Venture Management in Boston focused on Biotechnology and Medical. President & Board Member at MP Healthcare Venture Management.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 67% |
| Medical | 3 | 50% |
| Therapeutics | 3 | 50% |
| Health Care | 2 | 33% |
| Life Science | 1 | 17% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 67% |
| Series B | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 33% |
| United Kingdom | 2 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TRIMTECH Therapeutics | TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M | Seed | Jun 23, 2026 |  |
| TRIMTECH Therapeutics | TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $31M | Seed | Mar 05, 2025 |  |
| Outrun TX | Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway. | $10M | Seed | Apr 18, 2024 |  |
| PharmEnable | PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery of vital new medicines. | $7.5M | Seed | May 22, 2023 |  |
| QurAlis | QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $88M | Series B | Mar 09, 2023 |  |
| QurAlis | QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $5.5M | Seed | Nov 19, 2018 |  |

6 of 6 investments shown.

## Co-investors
- [Dementia Discovery Fund](https://shizune.co/investors/profile/dementia-discovery) — VC Fund, 3 deals together
- [M Ventures](https://shizune.co/investors/profile/merckventures) — VC Fund, 3 deals together
- [Mission BioCapital](https://shizune.co/investors/profile/bioinnovation-capital) — VC Fund, 2 deals together
- [Cambridge Enterprise Ventures](https://shizune.co/investors/profile/cambridge-enterprise-ventures) — VC Fund, 2 deals together
- [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital) — VC Fund, 2 deals together
- [Eli Lilly](https://shizune.co/investors/profile/eli-lilly) — VC Fund, 2 deals together

## About MP Healthcare Venture Management

VC Fund · Boston, United States

MPH is the venture capital arm of Mitsubishi Tanabe Pharma Corporation (MTPC). MPH invests in innovative companies developing novel therapeutics, platform technologies, and vaccines.

1 contacts available at MP Healthcare Venture Management.

| Name | Title | Profile |
| --- | --- | --- |
| Jeffrey Moore | President & Board Member | https://shizune.co/investors/profile/jeffrey-moore-2 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Jeffrey Moore invest in?

Jeffrey Moore invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Seed and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jeffrey Moore last invest?

The most recent investment recorded for Jeffrey Moore closed in Jun 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co